SNIP score for Translational Neurodegeneration is 1. Translational Neuroscience. Evolution of the number of total citation per document and external citation per document (i.e. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. Translational Neurodegeneration - Academic Accelerator Inclusion in an NLM database does not imply endorsement of, or agreement with, During the past ten years, we have been witnessing splendid progresses in TN. With the rapid advance in big data, genomics, proteomics, single cell analysis, and even single extracellular vesicle technology, we believe that a new horizon has just emerged in the fields of translational neurodegeneration. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. Wiley Bethesda, MD 20894, Web Policies Click to reveal Visitors may It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Source Normalized Impact per Paper (SNIP): 0.316. Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases, Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinsons disease dementia, Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China, Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study, An open-label multiyear study of sargramostim-treated Parkinsons disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers, Early life adversity as a risk factor for cognitive impairment and Alzheimers disease, A phase 1b randomized clinical trial of CT1812 to measure A oligomer displacement in Alzheimers disease using an indwelling CSF catheter, Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in China, COVID-19 and Alzheimers disease: how one crisis worsens the other, The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population, Immunotherapy for Alzheimers disease: targeting -amyloid and beyond, Recent progresses on early diagnosis of Parkinsons disease and related disorders, Clearance of neurotoxic proteins in proteinopathies: from clearance pathways to therapeutic targets, PD progresses in recent 10 years: from hypothesis to therapeutic targets, AD progresses in recent 10 years: from hypothesis to therapeutic targets, Mitochondria dysfunctions and neurodegenerative diseases, Update on Amyotrophic lateral sclerosis: from genetic and mitochondria perspective, Stem cell-based therapy for Alzheimers disease: the current situation and future prospects, Pharmacological treatment for early and advanced stages of Parkinsons disease: current and future strategies, See the full range of benefits of In Review and how to opt-in, See what the In Review platform looks like, Translational Neurodegeneration: 10th Anniversary, Sign up for article alerts and news from this journal, Source Normalized Impactper Paper (SNIP), Share their work withfellowresearcherstoread, comment on, and citeeven before publication, Showcase their work to funders and others with a citable DOI while it is still under review, Tracktheir manuscript- including seeing when reviewers are invited, and when reports are received. official website and that any information you provide is encrypted The latest ranking of Translational Neurodegeneration is 1426. Frontiers' philosophy is that all research is for the benefit of shows a rising trend. Impact Factor 10.7 (top 1%) extended IF 49 (top 8%) H-Index 315 authors 347 papers 8.8K citations 1.6K citing journals 9.8K citing authors Selected Period: - Re-Draw The graph shows the changes in the impact factor of Translational Neurodegeneration and its the corresponding percentile for the sake of comparison with the entire literature. ISSN 2666-1667. She has received Teaching Excellence Awards from Kings College London and the British Pharmacology Society in recognition of her innovative education. humankind. Each Frontiers article strives for the highest quality, thanks to therefore its fruits should be returned to all people without Translational Neurodegeneration | Home page 159.69.250.57 ISSN: 2081-3856. Translational Neurodegeneration is a journal published by BioMed Central Ltd.. Notably, the number of cases of dementia in the developed world is projected to rise from 13.5 million in 2000 to 21.2 million in 2025, and to 36.7 million in 2050. Translational Neuroscience Impact Factor IF 2022|2021|2020 - BioxBio Jialin C. Zheng, Email: nc.ude.ijgnot@gnehznilaij. Neurodegener.. Citation Impact 18.897 - 2-year Impact Factor (2021) 15.021 - 5-year Impact Factor (2021) 2.702 - Source Normalized Impact per Paper (SNIP) 4.731 - SCImago Journal Rank (SJR) Speed 22 days to first decision for all manuscripts (Median) 28 days to first decision for reviewed manuscripts only (Median) Usage 1,213,867 downloads (2022) It meets all the essential criteria of ISO 4 standard. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. 2023 BioMed Central Ltd unless otherwise stated. Should a dispute arise, authors or reviewers can trigger an arbitration and will alert the Associate Editor, who can assign more reviewers and/or bring the dispute to the attention of the Chief Editor. Research must be certified by peers before entering a stream of In 2022, Translational Neurodegeneration publsihed 5 articles. 1Translational Neurodegeneration, Departments of Neurology and Regenerative Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, China, 2Translational Neurodegeneration, Department of Neurology & Institute of Neurology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Find out more about the research published in Translational Neurodegeneration by reading our authors' Behind the Paperposts. 8600 Rockville Pike Your IP: Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. This website is using a security service to protect itself from online attacks. The IS0 4 standard abbreviation of Translational Neurodegeneration is Transl. An image of a cartoon face that is very unhappy. The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference. Sorry, this title is not available for purchase in your country/region. In TN, we will strive to do our utmost best to facilitate research to achieve these goals in the next ten years. That is why Frontiers provides online free and open access to all of This journal covers the area [s] related to Cellular and Molecular Neuroscience, Cognitive Neuroscience, Neurology (clinical), etc . Translational Neurodegeneration - SCI Journal We welcome our authors to share thestories behind their research on Springer Nature Neuroscience Community. Associate Editors oversee the peer-review and take the final acceptance decision on manuscripts. The .gov means its official. Its time you got more. The decision to accept an article needs to be unanimous amongst all reviewers and the handling Associate Editor. It is based on Scopus data. International Collaboration accounts for the articles that have been produced by researchers from several countries. This journal has received a total of 978 citations during the last three years (Preceding 2021). 2022 www.resurchify.com All Rights Reserved. appropriate credit is given and any changes specified. The International Standard Serial Number (ISSN) of Translational Neurodegeneration is/are as follows: 20479158. The names of the Associate Editor and reviewers are disclosed on published articles to encourage in depth and rigorous reviews, acknowledge work well done on the article and to bring transparency and accountability into peer-review. Correction: Olfactory swab sampling optimization for-synuclein aggregate detection inpatients with Parkinson's disease. The index is based on the set of the scientist's Many prominent scientists considered this journal to publish their scholarly documents including Pedro Rosa-Neto, Patrcio Soares-da-Silva, Anthony E. Lang, Serge Gauthier and Anthony E. Lang. It is computed in the year 2022. The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. Translational Approaches to Non-Motor Symptoms of Neurodegenerative Diseases, Volume 173 in the International Review on Neurobiology series, highlights new advances in the field with this new volume presenting interesting chapters on topics such as A general clinical overview of the non-motor symptoms, Stress/fatigue/cognitive decline Sleep/autonomic failure, A general clinical overview of the non-motor symptoms psychiatric symptoms, Psychosis, Cognitive Decline, Non-clinical Aspect of non-motor symptoms: Animal Models, Assessment and treatment of cognitive decline in rodent and primate models, Pain in PD models, Affective disorders in PD models, Sleep and circadian dysregulation and EEG disruption in rodent models, and much more. Bari, Italy. ACM Immediately download your ebook while waiting for your print delivery. It's publishing house is located in United Kingdom. (Australia) are fully compatible with publishing in Frontiers. The complexity of the peer review process and timeline. The h-index (also known as the Hirsch index or Hirsh index) is a scientometric parameter used to evaluate the scientific impact of the publications and journals. Springer Nature. The Associate Editor can also weigh in on the discussion and is asked to mediate the process to ensure a constructive revision stage. Volumes and issues. Translational Neuroscience. Volume 12 December 2023. Get access to Translational Neurodegeneration details, impact factor, Journal Ranking, H-Index, ISSN, Citescore, Scimago Journal Rank (SJR). In the first instance, achieving these goals, will be pursued by collaborating with colleagues at Kings College London. Affective disorders in PD models8. Translational Neurodegeneration. Chief Editors receive an honorarium if their specialty section or field reaches certain submission levels. Translational Neurodegeneration Factor de Impact 2021-2022 | Analiz Pain in PD models7. The reviewers are aided by an online standardized review questionnaire adopted to article types with the goal to facilitate rigorous evaluation according to objective criteria and the Frontiers Review Guidelines. We are with you every step of the way as you achieve your dreams - publication, everything that precedes it, and everything that comes after. Time taken from draft submission to final publication. There are several factors that influence the acceptance rate of any academic journal. At the beginning of 2022, we are celebrating the 10th birthday of our journal, Translational Neurodegeneration (TN). Follow us on @ScimagoJRScimago Lab, Copyright 2007-2022. Release: 886301575, Impact Score is a novel metric devised to rank conferences based on the number of contributing the best scientists in addition to the h-index estimated from the scientific papers published by the best scientists. Name The 2021-2022 Factor de Impact of Translational Neurodegeneration is 8.014, which is just updated in 2022. Impact Score 2021 of Translational Neurodegeneration is 8.86. Frontiers in Neuroscience | Translational Neuroscience The latest impact score (IS) of the Translational Neurodegeneration is 8.86. Associate Editor. There are also other factors such as H-Index, Self-Citation Ratio, SJR, SNIP, etc. The h-index of Translational Neurodegeneration is 45. The challenges in 2021 have continued to occur as we unceasingly fight against the pandemic. reviewers, who include many of the world's best scientists and scholars. Gut dysmotility in rodents and its central origin10. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. The number of BMC and Springer yearly downloads of TN publications was around 26,000 in 2012. Scope. Indexed in the following public directories, 414 articles received 11.6K citationssee all. Search. The Associate Editor initially checks that the article meets basic quality standards and has no obvious objective errors. Frontiers algorithms are constantly fine-tuned to better match Review Editors with manuscripts, and additional checks are being coded into the platform, for example regarding conflicts of interest. Springer Nature is the publisher of Translational Neurodegeneration. IS may increase in 2022 as well. Brain-derived neurotrophic factor in Alzheimer's disease and its Translational Neurodegeneration will continue to serve as a high-visibility forum to foster and expedite the rapid conversion of basic science and clinical research to benefit patients. An ISSN is a unique code of 8 digits. and transmitted securely. Cellular and Molecular Neuroscience (Q1); Cognitive Neuroscience (Q1); Neurology (clinical) (Q1). These new technologies along with multidisciplinary approaches will undoubtedly open new frontiers in discovering early diagnosis methods and developing treatment for these diseases. Unmasking neurodegenerative disease pathogenesis and identifying innovative diagnostics or therapeutics are the common goals of mainstream brain initiatives around the world. December 2022, issue 1; Volume 10 December 2021. MITPress. Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. Bladder dysfunction in rodent models of PD with a translational approach to bladder hyperreflexia in man11. This abbreviation ('Transl. For Translational Neurodegeneration, eISSN is 2047-9158 and pISSN is 2047-9158. please check the journal's official website to understand the complete publication process. Translational Neurodegeneration 3 Year Journal's Impact IF 2021-2022 | Trend, Prediction, Ranking, Key Factor Analysis Toolbox Journal Matcher Manuscript Generator Research Trend Ranking Conference Ranking Country Ranking Institution Ranking Journal Ranking Scholar Ranking Database Conference Database Journal Database Archive Database Manuscript and review quality at this stage are enhanced by allowing authors and reviewers to discuss directly with each other in real-time until they reach consensus and a final version of the manuscript is endorsed by the reviewers. System. Translational Neurodegeneration has been in operation since 2012 till date. It means 45 articles of this journal have more than 45 number of citations. Brief Research Report, Case Report, Clinical Trial, Community Case Study, Correction, Data Report, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Systematic Review, Technology and Code. Citation Impact 9.883 -2-year Impact Factor(2021) 9.260 -5-year Impact Factor(2021) 1.762 -Source Normalized Impactper Paper (SNIP) 1.849 - SCImago Journal Rank (SJR), Speed 8 days to first decision for all manuscripts (Median) 15 days to first decision for reviewed manuscripts only (Median), Usage 711,033 Downloads (2022) 573Altmetric mentions (2021). A key focus is to find drugs to combat the neurodegeneration underpinning Parkinsons. ISSN stands for International Standard Serial Number. disseminated to increasingly wider communities as it gradually climbs Frontiers General Conditions for Authors, authors of articles published in Frontiers journals retain copyright Jianqing Ding and Yuyan Tan, managing editors of Translational Neurodegeneration, to the leaders, colleagues, team members of Rui Jin Hospital. Molecular Neurodegeneration | Home page genuinely collaborative interactions between authors, editors and Accessibility Review Editors and reviewers are mandated to only accept to review a manuscript if they have no conflicts of interest (as stated here and in their review invitation and assignment emails). Authors are therefore free to disseminate and re-publish their The Frontiers platform enables post-publication commenting and discussions on papers and hence the possibility to critically evaluate articles even after the peer-review process. After a certain time frame and if no reviewers have in the meantime been assigned to the manuscript, the Frontiers platform and algorithmic safety-net steps in and invites the most appropriate Review Editors based on constantly updated and improved algorithms that match reviewer expertise with the submitted manuscript. We have identified the following critical areas for translational neurodegenerative diseases research: (1) To identify and validate biomarkers for early or pre-clinical diagnosis and for use as endpoints of clinical progression through strategies such as proteomics, genomics, metabolomics and functional imaging techniques in combination of artificial intelligence; (2) To promote clinical development through the latest innovative technologies such as neuroimaging strategies, stem cell technology, exosome technology and nanotechnology; and (3) To accelerate drug development and marketing through big cohort clinical trials; and more importantly, these clinical efforts will generate a multitude of new ideas and contacts that can be fed back for more focused/targeted research. We also thank Springer Nature, our publisher, for their help in making this fast-growing journal possible in the past ten years. Search About Journals, Conferences, and Book Series. All rights reserved. This is the number assigned to your article by the publisher, and it is the one you will use to reference your article within the library catalogues. Specifically, he will focus on the non-dopaminergic aspects of the parkinsonian pathology and role of inflammation in protein aggregation and the treatment of of l-dopa induced dyskinesia. Frontiers is well aware of the potential impact of published research There is no guarantee for this preference of choice, Associate Editors can decline invitations any time, and the handling Associate Editor can also be over-ridden by the Chief Editor before she/he is invited to edit the article or at any other stage. materials is always subject to any copyright notices displayed. The publication protocol for Translational Neurodegeneration is to publish new original papers that have been rigorously reviewed by competent scientific experts. Neurodegener.. Translational Neurodegeneration is a journal published by BioMed Central Ltd.. If your research field is/are related to Cellular and Molecular Neuroscience (Q1); Cognitive Neuroscience (Q1); Neurology (clinical) (Q1), then While we received only 31 submissions in 2012, in 2021 by Nov. 22nd the number of submissions has rocketed to 274. The latest SCImago Journal Rank (SJR) of Translational Neurodegeneration is 1.849. Translational Neuroscience provides a closer interaction between basic and clinical neuroscientists to expand understanding of brain structure, function and disease, and translate this knowledge into clinical applications and novel therapies of nervous system disorders. The section aims at publishing important basic research, as well as translational and clinical findings in the field of neurodegeneration. An image of a cartoon face with a neutral expression. For PD, the second most common neurodegenerative disease after AD, we are facing these daunting challenges as well. None have a financial incentive to accept articles, i.e. An official website of the United States government. The Translational Neurodegeneration is ranked 1426 among 27339 Journals, Conferences, and Book Series. *The metrics for this journal are compiled based on the data for scientists listed under SCImago Journal Rank (SJR indicator) is a measure of scientific influence which is reported in Science Translational Medicine, the . Translational Neurodegeneration - Impact Factor, Overall Ranking It is increased by a factor of around 1.2, and the percentage change is 15.67% compared to the preceding year 2020, indicating a rising trend. Improve your chances of getting published in Translational Neurodegeneration with Researcher.Life. Some of the critical parameters are listed below. Editorial decision power is distributed in Frontiers, because we believe that many experts within a community should be able to shape the direction of science for the benefit of society.